Annexon rolls out Guillain-Barré awareness campaign for HCPs amid promising results for targeted therapy
As it advances a monoclonal antibody targeting Guillain-Barré syndrome, Annexon Biosciences is embarking on another effort to improve treatment of the rare condition.
As it advances a monoclonal antibody targeting Guillain-Barré syndrome, Annexon Biosciences is embarking on another effort to improve treatment of the rare condition.
